Recent studies on the gene sequence encoding the human pyloric antral hormone, gastrin, indicate a precursor of 101 residues. We have now raised antibodies to a synthetic analogue corresponding to (Tyr)-human progastrin COOH-terminal pentapeptide. The antibodies could be used in radioimmunoassay to measure this peptide, but they did not react with corresponding fragments of procholecystokinin, porcine progastrin, Or other human progastrin-derived peptides, notably heptadecapeptide gastrin (G17), and 34-residue gastrin (G34). Radioimmunoassay of human antral and duodenal extracts revealed a major peak of activity that corresponded to the native COOH-terninal fragment of progastrin, and occurred in approximately equimolar amounts with COOH-terminal G17 immunoreactivity. In addition, there was a minor peak ofapparently higher molecular weight material. In some gastrinomas the latter material was the predominant immunoreactive form, and it occurred in higher molar concentrations than any other form of gastrin. Digestion of this material with trypsin liberated peptides that reacted with antibodies specific for the NH2-terminus of G34, and G17. On this basis the high molecular weight component was identified as a form of gastrin that extended from the COOH-termminus of the precursor to a point at least beyond the NHrterminus of G34, and probably included the entire progastrin sequence. The results suggest differences in posttranslational processing pathways of progastrin in antrum, duodenum and gastrinomas. They also indicate that the present experimental approach allows the identification of progastrin-like substances, which should open the way to studying the mechanisms of gastrin biosynthesis.
Introduction
Recently the complementary DNA (cDNA)' sequences complementary to the messenger RNA (mRNA) encoding porcine and human preprogastrin have been elucidated (1) (2) (3) (4) . These in- 1 . Abbreviations used in this paper: CCK, cholecystokinin; cDNA, complementary DNA; G17, heptadecapeptide gastrin; G34, 34-residue gastrin; HPLC, high pressure liquid chromatography; mRNA, messenger RNA; NT G34, NHrterminal fragment of G34; RSAEDEN, human progastrin 95-101; TFA, trifluoroacetic acid; TPCK, N-tosyl-L-phenylalanine chloromethyl ketone; YAEDEN, Tyr9" hutMan progastrin 97-103. dicate precursor peptides of 104 and 101 residues, respectively. In both instances there is a single copy of the sequence corresponding to 34-residue gastrin (G34), or big gastrin, isolated from pig antral mucosa and human gastrinoma tissue by Gregory and Tracy (5,' 6) . It has been appreciated for some time that G34 was a probable precursor of the major form of gastrin in antral tissue extracts, the heptadecapeptide, G17 (6) ..The latter, together with an NH2Iterminal fragment (NT G34), is generated by tryptic cleavage of G34 at pairs of Lys residues (6, 7) . In preprogastrin, G34 is extended at both NH2-terminal and COOH-terminal ends by peptide sequences that may be designated cryptic peptides A and B, respectively (Fig. 1) . Recently, antibodies to porcine cryptic peptides A and B were used to identify and localize these peptides in pig antrum (8, 9) . However, these antibodies do not react with the human cryptic peptides due to species differences in amino acid sequence (Scheme I).
We have now developed a radioimmunoassay using antibodies to a synthetic analogue of human cryptic peptide B, and have used it together with assays for G 17 and NT G34 to identify the peptides in extracts of human antrum, duodenum, and gastrinoma. Our results indicate the presence in these tissues of material corresponding to cryptic peptide B and to a larger peptide that may be intact progastrin and that in some gastrinomas is the predominant immunoreactive form.
Methods
Peptides. The hexapeptide Tyr-Ala-Glu-Asp-Glu-Asn (YAEDEN in the single-letter notation) was purchased from Peninsula Laboratories, Inc., Belmont, CA, in the form of crude synthetic material. It corresponds to (Tyr)-human progastrin 97-101 (Scheme I). The amino acid sequences in Scheme I are aligned from the Phe residue destined to become the COOH-terminal Phe amide ofgastrin orcholecystokinin (CCK). Cleavage at the arginine residues liberates cryptic peptide B, which in each case, starts with the tripeptide Ser-Ala-Glu. The COOH-terminal hexapeptide of human cryptic B substituted with Tyr in place of Ser, was used for immunization and radiolabeling in this study.
The Tissue samples. Extracts were prepared from eight gastrinomas (four samples of primary tumors and four of metastatic tissue), antral mucosa (n = 10), orduodenal tissue (n = 7) obtained at surgery. All the gastrinoma patients were diagnosed on the basis of a characteristic history of peptic ulcer disease, elevated basal plasma gastrin, positive secretin test, and basal acid output >10 mmol* h-'. Antral mucosa was obtained at resection for duodenal ulcer (n = 8), or carcinoma of the stomach (n -2). Duodenal samples, all of which were just distal to the sphincter of Oddi, were taken from patients undergoing Whipple's procedure. In all cases, the tissues were rapidly transported to the laboratory and either extracted immediately or frozen in liquid nitrogen and stored at -80'C before extraction.
Extraction. Fresh, or deeply frozen, tissue was extracted in boiling water. Small pieces of tissue (<0.1 g) were added to vigorously boiling water and heated for 5 min. Thereafter, the tissue was homogenized, the volume was made to 0.1 go ml-', and the extract was centrifuged. Supernatants were either stored frozen (-20'C) or were Iyophilized before further study. Re-extraction of pellets in either water or cold 3% acetic acid gave <10% of original immunoreactivity. Radioimmunoassay. Antibodies specific for human cryptic B were obtained by immunization of rabbits with YAEDEN. Peptide (570 nmol) was coupled to bovine thyroglobulin (1. (Fig. 2) . The synthetic peptide RSAEDEN also diluted in parallel with YAEDEN, whereas peptides corresponding to the COOH-terminal fragments of porcine progastrin and rat proCCK did not react significantly (<0.001); other progastrin-derived peptides, i.e., G 17, G34, and NT G34, were also inactive in the assay.
Antral mucosa. The concentration of cryptic B immunoreactivity in the antral extracts was 7.5±1.7 nmol * g-' (n = 10) compared with 5.4±0.9 nmol * g-' COOH-terminal G17 activity.
When antral extracts were fractionated on Sephadex G50 there was a major peak of cryptic B immunoreactivity that eluted in a similar position to the standard cryptic peptide and accounted for 84.3±2.1% of total activity (Fig. 3) . A minor peak of cryptic B immunoreactivity eluted just after the void volume and before G34, and contributed 12.3±1.6% to the total cryptic B immunoreactivity. In some column runs trace amounts of immunoreactivity (<2% total) emerged as a peak in the void volume, and as a peak just before the major peak. In all samples there were also major peaks corresponding to G 17 and NT G34 identified by the appropriate antibodies. Intact G34 was <5% total in all antral extracts. Duodenum. Cryptic B immunoreactivity was also found in duodenal extracts, although concentrations were 5 to 20 times lower than in antrum (mean, 0.51±0.20 nmol * g-', n = 7). The concentrations of COOH-terminal G17 immunoreactivity in the same extracts (0.42±0.16 nmol g-') were similar to those of cryptic B. The pattern of cryptic B immunoreactivity after separation on Sephadex G50 closely resembled that in the antral extracts (Fig. 4) . In contrast, assays using COOH-terminal GI 7 and NH2-terminal G34 antibodies showed that G34, rather than GI 7 and NT G34, predominated in the duodenal extracts.
Gastrinoma. The concentrations of cryptic B immunoreactivity in different tumor extracts ranged from 0.55 to 383 nmol g-' (mean, 108±53 nmol -g'; n = 8). By The early eluting peak accounted for most of the remaining activity; in three gastrinomas it was >50%, and in the group as a whole the mean was 39.7±6.5% (n = 8). Minor peaks eluting in the void, and between the two main peaks, accounted for 6 and 2%, respectively, of total activity. The predominant immunoreactive forms detected by antibodies to GI 7 and NT G34, corresponded to G 17 and NT G34 in all the gastrinoma extracts studied. HPLC and trypsinization. The high molecular weight cryptic B material in Sephadex eluates of gastrinoma extracts emerged as a single peak of immunoreactivity after reverse-phase HPLC (Fig. 7) . The low molecular weight material was poorly retained PERCENT ELUTION VOLUME PROTEIN To I25, Figure 5 . Separation on Sephadex G50 of a gastrinoma tumor extract. Tubes were assayed for cryptic B, NT G34, and COOH-terminal GI 7. See Fig. 3 for further details. PERCENT ELUTION VOLUME PROTEIN TO 1251 Figure 6 . Patterns of cryptic B immunoreactivity in three different tumor extracts after Sephadex G50 separation. Note the ratios of the two major peaks of immunoreactivity vary from >90% early eluting material (A) to 70% late eluting material (C). Minor peaks in the void volume and between the two main peaks can also be seen.
on HPLC and generally eluted with 0% acetonitrile (results not shown). The HPLC tubes corresponding to the high molecular weight cryptic peptide B contained trace amounts of activity in the COOH-terminal and NH2-terminal G17 and G34-specific assays. With NH2-terminal G34 assays the activity was -10% that in the cryptic peptide B assay; with NH2-terminal G 17 antibodies it was -1%, and with COOH-terminal G 17 antibodies it was 0.1%. Similar results were obtained when the material was rerun on a 1A Bondapak phenyl cartridge. When tubes in the eluates of both C18 and phenyl columns were digested with trypsin, the concentrations of cryptic B and ofCOOH-terminal G 17 immunoreactivity did not change (Fig. 7) . However, there was a marked increase in immunoreactivity with NH2-terminal GI 7 and G34 antibodies. The concentration measured in the latter two assays after trypsin closely matched, in molar terms, those of cryptic peptide B. When the peak tubes were rerun on C18, separate peaks corresponding to NH2-terminal G34, NH2-terminal G 17, and cryptic B immunoreactivity were resolved (Fig.  8) . The latter was poorly retained by the column and emerged before the gradient. In further experiments, crude extracts of antrum and gastrinomas were trypsinized and run on Sephadex.
In these experiments the early eluting peak of cryptic B immunoreactivity disappeared and there was a corresponding increase in the later eluting form (not shown). ofcryptic B in the human antrum (present study) and pig antrum (9) were also similar to those ofG 17. The stoichiometry ofthese peptides is therefore compatible with the idea that they are produced from the same precursor. In some gastrinomas, however, there was a poor correlation between the molar concentrations of G 17 (9) . In the pig we were unable to identify material that might have corresponded to intact progastrin. In this regard, 380 therefore, there is a difference between the pattern of immunoreactive forms in pig and man. The antral samples used for the present study were obtained from duodenal ulcer patients, and so the pattern of forms in normal human antral mucosa remains to be determined.
It is well established that there are different proportions of G 17 and G34 in human antrum and duodenum. The latter often contains over 50% G34 compared with <5% in antrum (15) (16) (17) . This can be interpreted as indicating different patterns of posttranslational processing of gastrin in antral and duodenal cells. It is of interest, however, that there were similar patterns ofcryptic peptide B immunoreactivity in duodenum and antrum. In both cases the predominant material had the chromatographic properties of the COOH-terminal fragment of progastrin. This suggests that the processing events involving cleavage of progastrin at the COOH-terminus ofGI7 are more or less complete in both antrum and duodenum, whereas those at the NH2 terminus of G17 are incomplete in duodenum.
Further work is needed to establish the basis for the different patterns of progastrin-derived peptides in tissues expressing the gastrin gene. Two possibilities might explain the differences between gastrinomas and antral mucosa found in the present study.
(a) There may be a biochemical failure in the processing pathways in some gastrinomas; and (b) the rate of production of the precursor may exceed the maximal rate of processing so that newly synthesized material accounts for a higher proportion of the tissue content in some gastrinomas. Further chemical studies on the identity of the progastrins, and the determination of the secretory patterns of the different immunoreactive forms may help resolve these issues.
